The European Commission has cleared the high-strength formulation of Eylea (aflibercept) with an extended treatment interval ...

At Longeveron, Dr. Joshua Hare and his team are working on an Alzheimer’s treatment using human-derived bone marrow ...

The UK is studying cases of pancreatitis in people taking drugs based on GLP-1 receptor agonists for weight loss or type 2 ...

An alternative to epinephrine autoinjectors that can be delivered by a nasal spray has been launched in Germany, its first ...

The licensing deal for BAFF/APRIL inhibitor telitacicept, which also includes regulatory and commercial milestones exceeding ...

Nektar, which accused Lilly of making errors in its analysis of the data, forged ahead with the programme and started the ...

It is not clear how AS01 might help lower the risk of dementia, but Oxford University said lab studies show that the adjuvant ...

Antisense-based therapy salanersen (BIIB115/ION306) is a possible follow-up to Biogen's big-selling Spinraza (nusinersen) therapy for SMA, which has come under pressure from increased competition in ...

As the CEO of ProofPilot, Chris Venezia has a track record of success with more than 18 years of strong leadership in product commercialisation, patient recruitment, marketing, and sales. He joined ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie.

Anne Wojcicki has asked the judge in bankruptcy proceedings for 23andMe, the genetic testing company she founded and led until earlier this year, to allow additional bids for the business.

Regeneron's PD-1 inhibitor Libtayo could find wider use for a form of skin cancer known as cutaneous squamous cell carcinoma after showing efficacy in a pivotal trial as adjuvant therapy for ...